Literature DB >> 8230307

Effect of in vivo exposure to iodine-131 on the frequency and persistence of micronuclei in human lymphocytes.

G K Livingston1, A E Foster, H R Elson.   

Abstract

The validity of the micronucleus test as a biomarker of chromosome damage in dividing mammalian cells is well established. This assay was used to study the response of peripheral lymphocytes of a 34-yr-old male patient following treatment with 131I ablative radiation therapy following a total thyroidectomy. Coincidentally, 8 mo before diagnosis, the patient had provided a blood sample for an in vitro study of micronucleus induction following exposure to graded doses of x-rays. The background frequency in the unexposed culture showed a mean count of 6.0 micronuclei per 1000 binucleated (first division) lymphocytes, while mean values of 18.5, 29.0, 41.0, 61.0 and 75.5 micronuclei/1000 cells were observed following x-ray doses of 5, 10, 15, 20, and 25 cGy, respectively. These data fit a nonthreshold, linear dose-response function (y = 2.78x + 3.71; r = .99). Eight months after the in vitro x-ray study, the subject was diagnosed with thyroid cancer. Surgery was performed, and 5 wk later the patient received 1.78 GBq (48 mCi) of 131I as adjuvant radiation therapy. Blood was drawn 11 d after the radiation treatment and at monthly intervals thereafter to analyze the frequency and persistence of micronuclei. The first posttreatment sample showed 35.5 micronuclei per 1000 binucleate cells. Based on the linear dose-response equation from the earlier study, the sixfold increase in micronucleus frequency suggests a dose to the peripheral blood of approximately 11 cGy. The cytogenetic dose estimate compares to approximately 30 cGy using a new model based on external whole-body counting data. Nine consecutive monthly samples have been analyzed to date. Although the micronucleus count has fluctuated (four- to sixfold above background), the frequency after 8 mo is equivalent to the first posttreatment sample. Data show that radiation-induced cellular lesions persist for months following relatively brief radiation exposure to a medical isotope. Results of this study support the conclusion that the lymphocyte micronucleus test is a rapid, sensitive, and perhaps quantitative biomarker of low-dose (< 25 cGy) radiation exposure.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8230307     DOI: 10.1080/15287399309531802

Source DB:  PubMed          Journal:  J Toxicol Environ Health        ISSN: 0098-4108


  8 in total

1.  Cytogenetic effects of radioiodine therapy: a 20-year follow-up study.

Authors:  Gordon K Livingston; Igor K Khvostunov; Eric Gregoire; Joan-Francesc Barquinero; Lin Shi; Satoshi Tashiro
Journal:  Radiat Environ Biophys       Date:  2016-03-25       Impact factor: 1.925

2.  Micronucleus formation in lymphocytes of children from the vicinity of Chernobyl after (131)I therapy.

Authors:  W-U Müller; S Dietl; K Wuttke; C Reiners; J Biko; E Demidchik; C Streffer
Journal:  Radiat Environ Biophys       Date:  2004-04-08       Impact factor: 1.925

3.  Iodine-131 treatment and chromosomal damage: in vivo dose-effect relationship.

Authors:  Taner Erselcan; Selma Sungu; Semra Ozdemir; Bulent Turgut; Derya Dogan; Ozturk Ozdemir
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-01-28       Impact factor: 9.236

4.  Evaluation of the cytogenetic effects of (131)I preceded by recombinant human thyrotropin (rhTSH) in peripheral lymphocytes of Wistar rats.

Authors:  Márcia Augusta da Silva; Maria Inês Calil Cury Guimarães; Hélio Yoriyaz; Maria Teresa Carvalho Pinto Ribela; Carlos Alberto Buchpiguel; Paolo Bartolini; Kayo Okazaki
Journal:  Radiat Environ Biophys       Date:  2008-08-19       Impact factor: 1.925

5.  Micronucleus frequency among Iraqi thyroid disorder patients.

Authors:  Abdul Hussein Moyet AlFaisal; Intesar Jawad Kahdoom Al-Ramahi; Ismail Abdul Redah Abdul-Hassan
Journal:  Comp Clin Path       Date:  2012-12-28

6.  No evidence of chromosome damage in children and adolescents with differentiated thyroid carcinoma after receiving 131I radiometabolic therapy, as evaluated by micronucleus assay and microarray analysis.

Authors:  Giovanni Federico; Giuseppe Boni; Barbara Fabiani; Lisa Fiore; Patrizia Lazzeri; Francesco Massart; Claudio Traino; Carmela Verola; Giuseppe Saggese; Giuliano Mariani; Roberto Scarpato
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-07-22       Impact factor: 9.236

7.  Persistent in vivo cytogenetic effects of radioiodine therapy: a 21-year follow-up study using multicolor FISH.

Authors:  Gordon K Livingston; Maria Escalona; Alvis Foster; Adayabalam S Balajee
Journal:  J Radiat Res       Date:  2018-01-01       Impact factor: 2.724

8.  Micronuclei Formation upon Radioiodine Therapy for Well-Differentiated Thyroid Cancer: The Influence of DNA Repair Genes Variants.

Authors:  Luís S Santos; Octávia M Gil; Susana N Silva; Bruno C Gomes; Teresa C Ferreira; Edward Limbert; José Rueff
Journal:  Genes (Basel)       Date:  2020-09-17       Impact factor: 4.096

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.